PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency

Summary

The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6. Native IL-6 and MPEG-IL-6, which showed about 51% of the specific bioactivity of native IL-6, were administered subcutaneously to mice every 2 days for 7 days. Native IL-6 increased not only the peripheral platelet count, but also the plasma-IgGl level in a dose-dependent manner. MPEG-IL-6 showed about 500 times higher thrombopoietic potency than native IL-6. Further, in comparison to native IL-6, MPEG-IL-6 did not enhance IgGl production as much as it enhanced platelet production. MPEG-IL-6 significantly stimulated platelet recovery in mice treated with 5-fluorouracil, whereas the administration of native IL-6 had a negligible effect. The plasma halflife of MPEG-IL-6 was about 100-fold longer than that of native IL-6. The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain. The uptake of IL-6 by the reticuloendothelial system, such as the liver and spleen, was markedly limited by PEGylation. The PEGylation of IL-6 markedly enhanced the blood-residency of IL-6, resulting in effective augmentation of its thrombopoietic activity and a marked decrease in its side-effects. These findings suggest that MPEG-IL-6 may be a potential candidate for thrombopoietic agent.

• References

• 1 Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopietic depression. Blood 1991; 77: 472-480
• 2 Berenbaum MC. Time-dependent and selectivity of immunosuppressive agents. Immunology 1979; 06: 355-365
• 3 Hoagland HC. Hematologic complications of cancer chemotherapy. Semin Oncol 1982; 09: 95-102
• 4 Carrington PA, Hill RJ, Levin J, Verotta D. Effects of interleukin 3 and interleukin 6 on platelet recovery in mice treated with 5-fluorouracil. Exp Hematol 1992; 20: 462-469
• 5 Sat K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851-856
• 6 Ishibashi T, Kimura H, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241-1244
• 7 Hill RJ, Warren MK, Stenberg P, Levin J, Corash L, Drummond R, Baker G, Levin F, Mok Y. Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 1991; 77: 42-78
• 8 Zeidler D, Kanz L, Hurkuck F, Rittmann KL, Wildfang I, Kadoya T, Mikayama T, Souza L, Welte K. In vivo effects interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood 1992; 80: 2740-2745
• 9 Hill RJ, Warren MK, Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest 1990; 85: 1242-1287
• 10 Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC, Plasma clearance. organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988; 177: 357-361
• 11 Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11: 499-506
• 12 Suematsu S, Matsuda T, Aozawa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. IgGl plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547-7551
• 13 Navarro S, Debili N, Le Couedic JP, Vainchenker W. Interleukin-6 and its receptor are expressed by human megakaryocytes. Blood 1991; 77: 461-471
• 14 Taga T. Role of two-chain IL-6 receptor system in immune and hematopoietic cell regulation. Critical Rev Immunol 1992; 11: 265-280
• 15 Bacchi CE, Rocha N, Carvalho M, Schmitt D, Schmitt F, Franco M. Immunohistochemical characterisation of probable intravascular haematopoiesis in the vasa rectae of the renal medulla in acute tubular necrosis. Pathol Res Pract 1994; 190: 1066-1070
• 16 Pedersen NT. The pulmonary vessels as a filter for circulating megakaryocytes in rats. Scand J Haemat 1974; 13: 225-231
• 17 Tsutsumi Y, Kihira T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, Horisawa Y, Kanamori T, Ikegami H, Mayumi T. Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its anti-tumor potency. Jpn J Cancer Res 1994; 85: 9-12
• 18 Tsutsumi Y, Kihira T, Tsunoda S, Kubo K, Miyake M, Kanamori T, Nakagawa S, Mayumi T. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-α completely regressed the solid tumor in the Meth-A murine sarcoma model. Jpn J Cancer Res 1994; 85: 1185-1188
• 19 Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S, Mayumi T. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995; 71: 963-968
• 20 Tsutsumi Y, Kihira T, Tsunoda S, Okada N, Kaneda Y, Miyake M, Ohsugi Y, Nakagawa S, Mayumi T. Polyethylene glycol-modification of interleukin-6 enhances its thrombopoietic activity. J Control Release 1995; 33: 447-441
• 21 Matsuda T, Hirano T, Kishimoto T. Establishment of an interleukin 6 (IL-6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur Immunol 1988; 18: 951-956
• 22 Ida N, Sakurai S, Hosaka T, Hosoi K, Kunitomo T, Shimazu T, Maruyama T, Matsuura Y, Kohase M. Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis. Biochem Biophys Res Commun 1989; 165: 728-734
• 23 Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrle P, Hinter-berger W, Lechner K, Liehl E, Mayer P. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992; 79: 1155-1160
• 24 Takatsuki F, Okano A, Suzuki C, Miyasaka Y, Hirano T, Kishimoto T, Ejima D, Akiyama Y. Interleukin perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res 1990; 50: 2885-2890